Primary Job Title Chairman of the Board and Chief Executive Officer Primary Organization Neuraptive Therapeutics
Location Greater Philadelphia Area, Pennsylvania, United States Regions Great Lakes, Northeastern US Gender Male
LinkedIn View on LinkedIn
Bob Radie is the Chairman of the Board and Chief Executive Officer at Neuraptive Therapeutics. He previously worked as the President, CEO at Egalet. From November 2010 to October 2011, Mr. Radie served as president and chief executive officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur in the fourth
quarter of 2011. From March 2009 to November 2010, Mr. Radie served as president and chief executive officer of Transmolecular, Inc., a biotechnology company developing cancer diagnostic and treatment products, after serving as a consultant to Transmolecular from December 2008 through March 2009. From September 2007 to September 2008, Mr. Radie served as the chief business officer of Prestwick Pharmaceuticals, Inc., a specialty pharmaceutical company. Before joining Prestwick, Mr. Radie served in senior management positions with a number of pharmaceutical and biotechnology companies, including Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and Eli Lilly and Company. Mr. Radie serves as a director Pennsylvania BIO, the statewide trade association for the life sciences in Pennsylvania, Paratek Pharmaceuticals, a biopharmaceutical company, and Horse Power for Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer. Mr. Radie received his B.S. in chemistry from Boston College.
